Overall verdict
Buy
6.5/10
1-year performance
+12.87%
Score breakdown
Up 12.9% over 1 year, 50% of the 52-week range.
Strongest: Valuation 8.9/10. Weakest: Growth 2.9/10.
28 analysts, target +0.2% vs the price.
CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans ; medical management capabilities ; Medicare Advantage and Medicare Supplement plans ; prescription drug plans (PDPs) ; and Medicaid health care management services.
It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail-order pharmacy, clinical services, disease management, medical spend management services, and pharmacy and other administrative services.
It serves employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, CMS, plans offered on public health insurance exchanges, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products.
This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nyse
United States
CEO
J. Joyner
Founded
1963
Employees
300 000
Revenue / employee
1.3M USD
Next earnings
February 10, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.42%
- FMR LLC1.94%
- Bank of New York Mellon Corp0.71%
- Rest of the register94.93%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
110.68 USD
52-week low
69.51 USD
1-year performance
12.87%
Rising
Year-to-date performance
13.48%
Rising
Drawdown
-18.71%
Marked drawdown
Position in the 52-week range
50% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned less, while shaking 1.8 times harder.
$10,000 placed at the end of December 2000 are worth today
| CVS Health | $48,399 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.8 times as much as the world ETF.
- Worst fall:-62 % between February 2001 and January 2003. $10,000 placed at the top fell to $3,762. The world ETF, at worst: -53 %. Back to its high in 30 months.
CVS Health earned less than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- CVS Health: $48,399
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 163.03 USD - 202.82 USD (2 methods agree)
The price implies growth of -8.32% per year; the company grows at -10.00%.
Gross margin 14.2%, net margin 2.6%, ROIC 7.4%, ROE 14.4%.
Net margin
2.62%
Low
Sector 4.74%|S&P 13.40%
Gross margin
14.23%
Low
Return on equity (ROE)
14.39%
High
Sector 10.36%|S&P 17.06%
Return on invested capital (ROIC)
7.41%
High
Free cash flow margin (FCF)
3.70%
Low
Profit-to-cash conversion (FCF conversion)
1.41x
High
Margin stability
1.2 pts
Very steady
Revenue to net income
Growth
2.9/10Revenue up 5.4% over 1 year, 8.4% a year over 5.
Revenue (trailing 12 months)
421Md USD
Revenue growth (1y)
5.36%
Moderate
Revenue growth (3y)
24.57%
Solid
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
4.01%
Revised up
Valuation
8.9/10P/E 10.5x, forward P/E 12.8x, EV/EBITDA 8.2x, PEG 0.00. The multiple sits in the 92th percentile of its own 5-year history.
P/E (TTM)
10.5x
Cheap
Sector 27.8x|S&P 23.6x
Forward P/E
12.8x
Cheap
EV / EBITDA
8.2x
Fair
Sector 12.6x|S&P 15.5x
PEG
0.00
Growth unpriced
Sector 0.52|S&P 0.91
Fair value (reverse DCF)
182.93 USD
Deeply undervalued
P/E vs its own 5-year history
among the 8% highest valuations
At its historical high
Market cap
115Md USD
Financial strength
3.2/10Cash covers 19.8% of the debt, net debt/EBITDA 4.1x.
Net debt / EBITDA
4.1x
Stretched
Gearing (net debt / equity)
74.87%
Tight
Cash
14.9Md USD
Cash / market cap
12.93%
Solid
Cash / total debt
19.77%
Tight
Interest coverage
4.9x
Tight
Net debt
60.4Md USD
Equity
80.7Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 89.01 USD
- MM2089.88
- MM5090.13
- MM20088.93
- RSI 1450.5
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.10%
200-day average slope, 3 months
+4.33%
50-day average slope, 1 month
-2.64%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
3.44 % per day
Volatility change
+93.71%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 7.05 (13) | 8.26 (23) | 421 722 (22) | 20 683 (9) | 9 052 (9) |
| 2027 | 7.28 (16) | 8.67 (26) | 430 894 (23) | 21 036 (11) | 9 381 (12) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 76 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DVA | 6.6 | 6.5 | 11.5Md USD | 13.9x | 6.3 % | 4.6 % | 7.5 % | 4.5x | 11.2 % | 52.1 % | ||
| 2 | CVS | 6.5 | 6.0 | 115Md USD | 10.5x | 2.6 % | 5.4 % | 7.4 % | 4.1x | 13.5 % | 12.9 % | ||
| 3 | HNGE | 6.4 | 7.0 | 9.5Md USD | 61.3x | 20.7 % | 52.4 % | 44.7 % | -1.6x | 3.3 % | 171.5 % | ||
| 4 | DGX | 6.1 | 6.1 | 28.5Md USD | 25.8x | 9.5 % | 10.0 % | 8.4 % | 2.8x | 4.8 % | 39.8 % | ||
| 5 | CI | 6.1 | 6.1 | 79.4Md USD | 13.3x | 2.1 % | 5.7 % | 8.3 % | 1.8x | 10.4 % | 15.8 % | ||
| 6 | BTSG | 6.0 | 4.7 | 14.5Md USD | 47.2x | 2.0 % | 26.4 % | 7.0 % | 4.6x | 3.4 % | 116.3 % | ||
| 7 | FME | 5.4 | 5.4 | 12.0Md USD | 13.6x | 4.2 % | 1.1 % | 3.8 % | 2.7x | 17.0 % | -0.5 % | ||
| 8 | GH | 5.3 | 3.6 | 20.9Md USD | Not meaningful (loss) | -37.9 % | 36.1 % | -41.6 % | -1.4x | -1.1 % | 59.9 % | ||
| 9 | LH | 5.3 | 4.4 | 30.2Md USD | 30.5x | 6.9 % | 6.9 % | 6.8 % | 2.4x | 4.3 % | 41.7 % |
